Societal CDMO, Inc.

SCTL

US75629F1093

Pharmaceuticals

Market Closed - Nyse Other stock markets 04:00:00 2024-04-05 pm EDT			5-day change	1st Jan Change
1.1 ^USD	+0.92%		-.--%	+213.84%

Apr. 08	Societal CDMO, Inc. Announces Board and Committee Resignations	CI
Apr. 08	Societal CDMO, Inc.(NasdaqCM:SCTL) dropped from NASDAQ Composite Index	CI

Societal CDMO, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023

August 14, 2023 at 04:05 pm EDT

Societal CDMO, Inc. reported earnings results for the second quarter and six months ended June 30, 2023. For the second quarter, the company reported sales was USD 21.8 million compared to USD 23.15 million a year ago. Net loss was USD 3.21 million compared to USD 3.12 million a year ago. Diluted loss per share from continuing operations was USD 0.04 compared to USD 0.06 a year ago.
For the six months, sales was USD 43.33 million compared to USD 44.35 million a year ago. Net loss was USD 7.9 million compared to USD 7.38 million a year ago. Diluted loss per share from continuing operations was USD 0.09 compared to USD 0.13 a year ago.

Latest news about Societal CDMO, Inc.

Societal CDMO, Inc. Announces Board and Committee Resignations	Apr. 08	CI
Societal CDMO, Inc.(NasdaqCM:SCTL) dropped from NASDAQ Composite Index	Apr. 07	CI
CoreRx, Inc. completed the acquisition of Societal CDMO, Inc. from First Light Asset Management, LLC and Others.	Apr. 07	CI
Societal CDMO, Inc.(NasdaqCM:SCTL) dropped from S&P TMI Index	Apr. 07	CI
North American Morning Briefing : Stocks Edge -2-	Mar. 27	DJ
Societal CDMO, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	Mar. 22	CI
North American Morning Briefing : Markets on Hold -2-	Mar. 20	DJ
Stephens Downgrades Societal CDMO to Equalweight From Overweight, Raises Price Target to $1.10 From $1	Feb. 29	MT
William Blair Downgrades Societal CDMO to Market Perform From Outperform	Feb. 29	MT
Wall Street Set to Open Higher Thursday as Inflation Data Meets Forecasts	Feb. 29	MT
Investors Await Slate of Economic Data as US Futures Move Lower in Thursday's Premarket Session	Feb. 29	MT
RBC Downgrades Societal CDMO to Sector Perform From Outperform, Trims Price Target to $1.10 From $1.25 Amid CoreRx Deal	Feb. 29	MT
CoreRx, Inc. entered into a definitive agreement to acquire Societal CDMO, Inc..	Feb. 27	CI
Societal CDMO Signs Co-Marketing Deal With Benuvia Operations	Feb. 01	MT
Societal CDMO, Inc and Benuvia Sign Co-Marketing Agreement Designed to Promote Complementary CDMO and API Manufacturing Services to Drug Developers	Feb. 01	CI
Certain Warrants of Societal CDMO, Inc. are subject to a Lock-Up Agreement Ending on 23-NOV-2023.	Nov. 22	CI
Certain Restricted Stock Units of Societal CDMO, Inc. are subject to a Lock-Up Agreement Ending on 23-NOV-2023.	Nov. 22	CI
Certain Stock Options of Societal CDMO, Inc. are subject to a Lock-Up Agreement Ending on 23-NOV-2023.	Nov. 22	CI
Certain Common Stock of Societal CDMO, Inc. are subject to a Lock-Up Agreement Ending on 23-NOV-2023.	Nov. 22	CI
RBC Cuts Price Target on Societal CDMO to $1.25 From $2, Keeps Outperform Rating	Nov. 09	MT
Transcript : Societal CDMO, Inc., Q3 2023 Earnings Call, Nov 08, 2023	Nov. 08
Earnings Flash (SCTL) SOCIETAL CDMO Posts Q3 Revenue $23.6M, vs. Street Est of $24.3M	Nov. 08	MT
Societal CDMO, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	Nov. 08	CI
Societal CDMO, Inc. Resets Earnings Guidance for the Year 2023	Nov. 08	CI
Societal CDMO, Inc. Reduces its Workforce by 26 Positions Across All Aspects of the Business	23-09-21	CI

Chart Societal CDMO, Inc.

Duration

Period

More charts

Company Profile

Societal CDMO, Inc. is a bi-coastal contract development and manufacturing organization (CDMO). The Company is engaged in spanning pre-investigational new drug development to commercial manufacturing and packaging for a range of therapeutic dosage forms with a primary focus in the area of small molecules. It is a CDMO providing therapeutic development, end-to-end regulatory support, clinical and commercial manufacturing, aseptic fill/finish, lyophilization, packaging and logistics services to the global pharmaceutical market. The Company's key products include Ritalin LA, Focalin XR, Verelan PM, Verelan SR, Verapamil PM, Verapamil SR and Donnatal liquids and tablets. Its manufacturing and development capabilities include product development from formulation through clinical trial and commercial manufacturing, and specialized capabilities for solid oral dosage forms, with specialization in modified release technologies and facilities to handle potent compounds and controlled substances.

Sector

Pharmaceuticals

Calendar

2024-05-07 - Q1 2024 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Sector Other Pharmaceuticals

	1st Jan change	Capi.
SOCIETAL CDMO, INC.	+213.84%	116M
ELI LILLY AND COMPANY	+34.00%	704B
NOVO NORDISK A/S	+29.29%	577B
JOHNSON & JOHNSON	-7.75%	348B
MERCK & CO., INC.	+18.53%	327B
ABBVIE INC.	+4.95%	288B
ASTRAZENECA PLC	+13.79%	234B
NOVARTIS AG	+4.93%	198B
ROCHE HOLDING AG	-9.78%	194B
AMGEN INC.	-4.89%	147B